Mycoplasma pneumoniae: Susceptibility and Resistance to Antibiotics

Cécile Bébéar; Sabine Pereyre; Olivia Peuchant


Future Microbiol. 2011;6(4):423-431. 

In This Article

Conclusion & Future Perspective

Effective management of M. pneumoniae infections can be easily achieved with macrolides, tetracyclines or fluoroquinolones; however, the recent emergence of macrolide resistance, first in Japan but now worldwide, affecting mainly children but also adults, is of concern. This makes epidemiological surveillance of macrolide resistance in M. pneumoniae a necessity in Europe, USA and Asia in pediatric and adult patients with respiratory infections. Development of real-time PCR methods for rapid detection of mutations in the 23S rRNA, which confers macrolide resistance, directly from respiratory specimens, appears very promising and should allow treatment to be adjusted rapidly in case a resistant genotype is detected. Furthermore, development of standardized methods with appropriate quality control measures to perform antibiotic susceptibility testing is now being achieved and will be useful to monitor the spread of macrolide resistance.

Futher studies are also needed to clarify the impact of macrolide resistance on the outcomes of respiratory infections, such as the two studies reported from Japan[33,48] and to establish clinical guidelines regarding the most appropriate antimicrobial agents to use against these resistant strains.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: